×
About 1,304 results

ALLMedicine™ Hypereosinophilic Syndrome Center

Research & Reviews  639 results

Autoantibody profile in eosinophilic granulomatosis and polyangiitis: predominance of a...
https://www.ncbi.nlm.nih.gov/pubmed/33200729
Clinical and Experimental Rheumatology; Laskari K, Hellmich B et. al.

Nov 17th, 2020 - To evaluate the autoantibody profile in eosinophilic granulomatosis and polyangiitis (EGPA) patients. 33 EGPA patients were tested for anti-neutrophil cytoplasmic antibodies (ANCA), antinuclear antibodies (ANA), rheumatoid factor (RF), anti-alpha-...

Pathological entities that may affect the lungs and the myocardium. Evaluation with che...
https://doi.org/10.1016/j.clinimag.2020.10.038
Clinical Imaging; Sanchez F, Gutierrez JM et. al.

Nov 6th, 2020 - Certain entities may simultaneously involve the lungs and the myocardium. Knowing their cardiac and thoracic manifestations enhances the understanding of those conditions and increases awareness and suspicion for possible concurrent cardiothoracic...

Loeffler's Endocarditis: An Integrated Multimodality Approach.
https://doi.org/10.1016/j.echo.2020.09.002
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography; Polito MV, Hagendorff A et. al.

Nov 1st, 2020 - Loeffler's endocarditis (LE) is the cardiac manifestation of hypereosinophilic syndrome, a rare systemic disease characterized by the sustained production of eosinophils leading to organ damage. Few data, principally by case reports, are available...

A flare up of idiopathic hypereosinophilic syndrome due to COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665460
European Heart Journal; Laleh Far V, Najafizadeh SR et. al.

Oct 27th, 2020 - A flare up of idiopathic hypereosinophilic syndrome due to COVID-19.|2020|Laleh Far V,Najafizadeh SR,Eslami M,Mollazadeh R,|

Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2...
https://doi.org/10.1097/PAS.0000000000001604
The American Journal of Surgical Pathology; Fernandez-Pol S, Petersen B et. al.

Oct 16th, 2020 - Lymphocyte variant hypereosinophilic syndrome (LV-HES) is a rare cause of eosinophilia that is due to eosinophilipoietic cytokine production by an immunophenotypically abnormal T-cell clone. The molecular pathogenesis of this disorder is largely u...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  655 results

Autoantibody profile in eosinophilic granulomatosis and polyangiitis: predominance of a...
https://www.ncbi.nlm.nih.gov/pubmed/33200729
Clinical and Experimental Rheumatology; Laskari K, Hellmich B et. al.

Nov 17th, 2020 - To evaluate the autoantibody profile in eosinophilic granulomatosis and polyangiitis (EGPA) patients. 33 EGPA patients were tested for anti-neutrophil cytoplasmic antibodies (ANCA), antinuclear antibodies (ANA), rheumatoid factor (RF), anti-alpha-...

Pathological entities that may affect the lungs and the myocardium. Evaluation with che...
https://doi.org/10.1016/j.clinimag.2020.10.038
Clinical Imaging; Sanchez F, Gutierrez JM et. al.

Nov 6th, 2020 - Certain entities may simultaneously involve the lungs and the myocardium. Knowing their cardiac and thoracic manifestations enhances the understanding of those conditions and increases awareness and suspicion for possible concurrent cardiothoracic...

Loeffler's Endocarditis: An Integrated Multimodality Approach.
https://doi.org/10.1016/j.echo.2020.09.002
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography; Polito MV, Hagendorff A et. al.

Nov 1st, 2020 - Loeffler's endocarditis (LE) is the cardiac manifestation of hypereosinophilic syndrome, a rare systemic disease characterized by the sustained production of eosinophils leading to organ damage. Few data, principally by case reports, are available...

A flare up of idiopathic hypereosinophilic syndrome due to COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665460
European Heart Journal; Laleh Far V, Najafizadeh SR et. al.

Oct 27th, 2020 - A flare up of idiopathic hypereosinophilic syndrome due to COVID-19.|2020|Laleh Far V,Najafizadeh SR,Eslami M,Mollazadeh R,|

Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2...
https://doi.org/10.1097/PAS.0000000000001604
The American Journal of Surgical Pathology; Fernandez-Pol S, Petersen B et. al.

Oct 16th, 2020 - Lymphocyte variant hypereosinophilic syndrome (LV-HES) is a rare cause of eosinophilia that is due to eosinophilipoietic cytokine production by an immunophenotypically abnormal T-cell clone. The molecular pathogenesis of this disorder is largely u...

see more →

News  5 results

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.staging.medscape.com/viewarticle/938221

Sep 27th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.medscape.com/viewarticle/938221

Sep 27th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

CHMP recommends approval of generic imatinib
https://www.mdedge.com/hematology-oncology/article/185423/cythemias/chmp-recommends-approval-generic-imatinib
HT Staff

Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.

Imatinib Mesylate–Induced Lichenoid Drug Eruption
https://www.mdedge.com/dermatology/article/132728/nonmelanoma-skin-cancer/imatinib-mesylate-induced-lichenoid-drug-eruption/page/0/1

Mar 6th, 2017 - Comment In addition to CML, imatinib has been approved for acute lymphoblastic leukemia, myelodysplastic syndromes, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and G.

AACR: Gleevec Effective in Rare Myeloproliferative Disorder
https://www.medpagetoday.com/hematologyoncology/hematology/2977

Apr 2nd, 2006 - Action Points Be aware that this study found Gleevec effective and safe in patients with idiopathic hypereosinophilic syndrome (HES) who have a translocation between the FIP1L1 and PDGFR genes. This is an off-label use of Gleevec. This study was p...

see more →

Patient Education  3 results see all →